Imeglimin.

Abstract

Glycemic control for type 2 diabetes continues to be a global concern, with diabetes entering the top 10 causes of death globally, at number nine, in 2020 (1). Studies have found that glycemic control has declined in the last several years, with <60% of patients meeting their A1C goal in 2014 (2). A more recent review found that young adults with type 2 diabetes have worse glycemic control than past cohorts, with an average A1C of 8.5% (3). There are many challenges to the management of diabetes, including high health care costs, poor patient adherence, and contraindications to and side effect profiles of available drug classes that limit their use.